The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Iakupov É.Z.

Kafedra nevrologii, neĭrokhirurgii i meditsinskoĭ genetiki Kazanskogo gosudarstvennogo meditsinskogo universiteta

Artemieva D.V.

Kazan State Medical University, Kazan, Russia

Troshina Iu.V.

GBOU VPO "Kazanskiĭ gosudarstvennyĭ meditsinskiĭ universitet", Kazan'

Multimodality of clinical effects of orexin

Authors:

Iakupov É.Z., Artemieva D.V., Troshina Iu.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12): 114‑119

DOI: 10.17116/jnevro2018118121114

Read: 7298 times

Download PDF (RU)
Contact the author
Table of contents

MULTIMODALITY OF CLINICAL EFFECTS OF OREXIN
MULTIMODALITY OF CLINICAL EFFECTS OF OREXIN

To cite this article:

Iakupov ÉZ, Artemieva DV, Troshina IuV. Multimodality of clinical effects of orexin. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12):114‑119. (In Russ.)
https://doi.org/10.17116/jnevro2018118121114

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Vali­dation of ballistocardiography data for predicting the sleep effi­ciency in healthy indi­viduals and patients with inso­mnia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):60-66
Carbonyl stress in meno­pausal women with inso­mnia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):192-197
Subjective sleep quality evaluation in patients with neuromyelitis optica spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):57-61
Sleep deprivation and the deve­lopment of oxidative stress in animal models. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):124-129
The state of mental health of migrant workers and citi­zens of the Russian Fede­ration: A comparative analysis as illu­strated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101
Inso­mnia in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):46-51
The use of zolpidem in the treatment of acute and chro­nic inso­mnia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):52-56
The pote­ntial of neurofeedback control in treating inso­mnia and improving sleep quality (a systematic review). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):57-63
Effe­cts of rhythmic transcranial magnetic stimulation in the treatment of inso­mnia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):64-69
Sleep diso­rders in imprinting diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):75-80
Abstract:

The article describes the main biological properties of orexin as a wakefulness hormone and its possible points of application in practical medicine. An example of a drug, which blocks orexin receptors and can be used as a hypnotic drug to treat sleep disorders, is presented.

Keywords:

orexin
hypocretin
insomnia
sleep disorders
circadian rhythm

Authors:

Iakupov É.Z.

Kafedra nevrologii, neĭrokhirurgii i meditsinskoĭ genetiki Kazanskogo gosudarstvennogo meditsinskogo universiteta

Artemieva D.V.

Kazan State Medical University, Kazan, Russia

Troshina Iu.V.

GBOU VPO "Kazanskiĭ gosudarstvennyĭ meditsinskiĭ universitet", Kazan'

Close metadata

References:

  1. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS 2nd, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95(1):322-327. https://doi.org/10.1073/pnas.95.1.322
  2. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573-585. https://doi.org/10.1016/S0092-8674(00)80949-6
  3. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365-376. https://doi.org/10.1016.S0092-8674(00)81965-0
  4. Challet E, Pevet P, Malan A. Effect of prolonged fasting and subsequent refeeding on free-running rhythms of temperature and locomotor activity in rats. Behav Brain Res. 1997;84:275-284. https://doi.org/10.1016/S0166-4328(97)83335-9
  5. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355(9197):39-40. https://doi.org/10.1016/S0140-6736(99)05582-8
  6. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6(9):991-997. https://doi.org/10.1038/79690
  7. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27(3):469-474. https://doi.org/10.1016/S0896-6273(00)00058-1
  8. Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, Marcus JN, Lee C, Elmquist JK, Kohlmeier KA, Leonard CS, Richardson JA, Hammer RE, Yanagisawa M. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron. 2003;38(5):715-730. https://doi.org/10.1016/S0896-6273(03)00330-1
  9. Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, Tominaga M, Yagami Ki, Sugiyama F, Goto K, Yanagisawa M, Sakurai T. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron. 2003;38(5):701-713. https://doi.org/10.1016/S0896-6273(03)00331-3
  10. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA. 2004;101(13):4649-4654. https://doi.org/10.1073/pnas.0400590101
  11. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu C, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007;13(2):150-155. https://doi.org/10.1038/nm1544
  12. Wang Z, Liu S, Kakizaki M, Hirose Y, Ishikawa Y, Funato H, Yanagisawa M, Yu Y, Liu Q. Orexin/hypocretin activates mTOR complex 1 (mTORC1) via an Erk/Akt-independent and calcium-stimulated lysosome v-ATPase pathway. J Biol Chem. 2014;289(46):31950-31959. https://doi.org/10.1074/jbc.M114.600015
  13. Muroya S, Funahashi H, Yamanaka A, Kohno D, Uramura K, Nambu T, Shibahara M, Kuramochi M, Takigawa M, Yanagisawa M, Sakurai T, Shioda S, Yada T. Orexins (hypocretins) directly interact with neuropeptide Y, POMC and glucose-responsive neurons to regulate Ca2+ signaling in a reciprocal manner to leptin: orexigenic neuronal pathways in the mediobasal hypothalamus. Eur J Neurosci. 2004;19(6):1524-1534. https://doi.org/10.1111/j.1460-9568.2004.03255.x
  14. Poluektov MG. Sleep disorders in neurological practice. Neurology, neurosurgery, psychiatry. 2012;4(4):12-24. (In Russ.) https://doi.org/10.14412/2074-2711-2012-416
  15. Arnulf I, Zeitzer M, File J, Farber N. Kleine—Levin Syndrome Foundation. Brain. 2005;28(12):2763-2776. https://doi.org/10.1093/brain/awh620
  16. Afshar K, Engelfried K, Sharma OP. Sarcoidosis: a rare cause of Kleyne—Levin syndrome. Vasc Diffuse Lung Dis. 2008;25(1):60-63.
  17. Kovalzon VM, Zavalko IM. Neurochemistry of sleep/wake cycle in Parkinson’s disease. Neurochemistry. 2013;30(3):193-206. (In Russ.)
  18. Gusev EI, Gecht AB, Popov GR, Volkova NA, Pastukhova YuF, Pronina TS, Chesnokova AYu, Ekimova IV. Neurodegenerativa diseases. Fundamental aspects and applications. M.: Nauka; 2010. (In Russ.)
  19. Zoccolella S, Savarese M, Lamberti P, Manni R, Pacchetti C, Logroscino G. Sleep disorders and the natural history of Parkinson’s disease: the contribution of epidemiological studies. Sleep Med Rev. 2011;15(1):41-50. https://doi.org/10.1016/j.smrv.2010.02.004
  20. Silkis IG. Search for approaches to the correction of daytime sleepiness caused by dopaminergic drugs in the treatment of Parkinson’s disease: neurochemical aspects. Neurochemistry. 2009;26(3):253-264. (In Russ.)
  21. Arnulf I, Bonnet A-M, Damier P, Bejjani B-P, Seilhean D, Derenne J-P, Agid Y. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology. 2000;55(2):281-288. https://doi.org/10.1212/WNL.57.7.1350-a
  22. Fronczek R, Overeem S, Lee SYY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF. Hypocretin (orexin) loss in Parkinson’s disease. Brain. 2007;130(6):1577-1585. https://doi.org/10.1093/brain/awm090
  23. Fronczek R, Overeem S, Lee SYY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF. The brain hypocretins and their receptors: mediators of allostatic arousal. Brain. 2008;9(1):39-45. https://doi.org/10.1016/j.coph.2008.12.018
  24. Thannickal TC, Lai Y-Y, Siegel JM. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain. 2007;130(6):1586-1595. https://doi.org/10.1093/brain/awm097
  25. Thannickal TC, Lai Y-Y, Siegel JM. Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson’s disease. Brain. 2008;131(1):e87. https://doi.org/10.1093/brain/awm221
  26. Lagos P, Torterolo P, Jantos H, Monti JM. Immunoneutralization of melanin-concentrating hormone (MCH) in the dorsal raphe nucleus: effects on sleep and wakefulness. Brain Res. 2011;1369:112-118. https://doi.org/10.1016/j.brainres.2010.11.027
  27. Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M, Sakurai T. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res. 2000;873:181-187. https://doi.org/10.1016/S0006-8993(00)02555-5
  28. Baumann CR, Scammell TE, Bassetti CL. Parkinson’s disease, sleepiness and hypocretin/orexin. Brain. 2008;131:e91. https://doi.org/10.1093/brain/awm220
  29. Bassetti CL, Baumann CR, Scammell TE. Narcolepsy: Pathophysiology, Diagnosis, and Treatment. Springer. 2011. https://doi.org/10.1007/978-1-4419-8390-9
  30. Wienecke M, Werth E, Poryazova R, Baumann-Vogel H, Bassetti CL, Weller M, Waldvogel D, Storch A, Baumann CR. Progressive dopamine and hypocretin deficiencies in Parkinson’s disease: is there an impact on sleep and wakefulness? J Sleep Res. 2012;21(6):710-717. https://doi.org/10.1111/j.1365-2869.2012.01027.x
  31. Shumilov EG. Participation of orexin structures of the extended amygdala in the reinforcing action of drug genes: Dis. … kand. med. nauk. SPb. 2016. (In Russ.)
  32. Petrov AM, Giniatullin AR. Nejrobiologiya sna: sovremennyj vzglyad. Uchebnoe posobie. Kazan’: Izdatel’stvo Kazanskogo gosudarstvennogo medicinskogo universiteta; 2012. (In Russ.)
  33. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996-10015. https://doi.org/10.1007/978-1-4419-8390-9
  34. Citrome L. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for the newly approved hypnotic — what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Int J Clin Pract. 2014;68:1429-1441. https://doi.org/10.1111/ijcp.12568
  35. Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, Roecker AJ, Mercer SP, Bednar RA, Lemaire W, Bruno JG, Reiss DR, Harrell CM, Murphy KL, Garson SL, Doran SM, Prueksaritanont T, Anderson WB, Tang C, Roller S, Cabalu TD, Cui D, Hartman GD, Young SD, Koblan KS, Winrow CJ, Renger JJ, Coleman PJ. Discovery of the dual orexin receptor antagonist methanone (MK-4305) for the treatment of insomnia. J Med Chem. 2010;53:5320-5332. https://doi.org/10.1021/jm100541c
  36. Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Promotion of sleep by MK-4305 — a novel dual orexin receptor antagonist. J Neurogenet. 2011;25:52-61. https://doi.org/10.3109/01677063.2011.566953
  37. Herring JW, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79:2265-2274. https://doi.org/10.1212/WNL.0b013e31827688ee.
  38. Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials. Journal of Clinical Sleep Medicine. 2016;12(9):1215-1225. https://doi.org/10.5664/jcsm.6116
  39. Michelson D, Snyder E, Pardis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double blind, placebo-controlled trial. Lancet Neurol. 2014;13:461-471. https://doi.org/10.1016/S1474-4422(14)70053-5
  40. Michelson D. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016. https://doi.org/10.1016/S1474-4422(14)70053-5
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.